A Phase 3 clinical trial involving ganirelix began recruiting as of September 21, 2026. The study, registered as NCT07108621, is titled "hCG Priming in Women With Diminished Ovarian Reserve." According to its listing on ClinicalTrials.gov, the trial is currently in the recruiting stage. The trial is designated Phase 3 in the registry. No results have been posted for this study at this time. The listing does not provide additional details on trial design, endpoints, or expected completion within the fields reported here. Ganirelix is an approved compound, and its use in this trial reflects an investigation specific to this study population. Readers interested in the status of this research can consult the ClinicalTrials.gov registry entry for updates as the trial progresses. For more background on ganirelix, including its approved uses, readers can refer to the compound overview.
Phase 3 Trial of hCG Priming With Ganirelix Now Recruiting
See the full ganirelix overview
Source: https://clinicaltrials.gov/study/NCT07108621